What happened

After the Food and Drug Administration approved collaboration partner Clinical Reference Laboratory's saliva test for COVID-19, Co-Diagnostics (NASDAQ:CODX) shares soared 28.3% on Monday.

So what

One of the biggest private lab companies in the United States, Clinical Reference Laboratory (CRL) developed its saliva COVID-19 test using Co-Diagnostics CoPrimer technology to boost sensitivity and reduce false positives by eliminating amplification errors common in molecular testing.

A toy rocket soaring into the sky.

IMAGE SOURCE: GETTY IMAGES.

The FDA's emergency-use approval for CRL's test using CoPrimer techology isn't the first for Co-Diagnostics, though. The healthcare company secured FDA emergency-use authorization for its Logix Smart Coronavirus Disease 2019 (COVID-19) test in April, and on May 14, it reported unaudited COVID-19-related revenue of $18 million year to date. 

Now what

The rapid spread of Covid-19 is contributing to a backlog of testing demand that's causing delays in test results, so there's a significant need for new testing capacity. 

The potential tailwind to Co-Diagnostics revenue from COVID-19-related testing is significant since the company's total revenue was just $1.5 million in the first quarter. Given the sales numbers reported in May and increasing testing in the United States throughout the past quarter, it appears a big quarter-over-quarter increase in revenue is on tap when management reports second-quarter results on August 13.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.